AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06410911 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Erector Spinae Block in patients undergoing open cholecystectomy
Description: Ultrasound-guided Erector Spinae block using 20 mL of 0.25% bupivacaine will be injected bilaterally at the T7- T8 vertebral level in patients undergoing open cholecystectomy The probe will be advanced 3 cm to the right lateral direction and rotated 90 degrees, and the transverse processes will be determined . Next, 5 mL of 2% lidocaine will be administered to the predicted needle entry point. A 22-gauge, peripheral nerve block needle will cephalocaudally advanced by the in-plane technique. The needle tip will be continuously advanced toward the transverse process to 1-2 mm before contact with the transverse process. After negative aspiration, 20 ml of 0.25% bupivacaine will be injected with intermittent negative aspirations into the fascia of the erector spinae muscle.
Study NCT06410911 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sbcostal transversus Abdominis block and erector spinae block for both groups
Description: Each patients group will recieve a type of block by injecting 20 ml of 0.25% bupivacaine on each side in patients undergoing open cholecystectomy
Study NCT05080621 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ripretinib
Description: 50 mg tablets
Study NCT05080621 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: binimetinib
Description: 15 mg tablets
Study NCT05560516 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Qutenza
Description: Capsaicine patch: Qutenza 8% patch will be applied to the skin according to the instruction of the manufacturer. After application of local anesthetics on the skin, a Qutenza 8% patch will be placed. 1-4 patches will be placed and can be adjusted to the right size, depending on the surface of the CIPN. The patch(es) will be removed after 30-60 minutes. The effect will last about 12 weeks.
Study NCT05560516 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Duloxetine
Description: Duloxetine tablets: In week 1 patients will receive 30 mg duloxetine one time per day. In week 2 the dose will be increased to 60 mg one time per day. In case of inacceptable adverse events the patient is allowed to reduce the dose to 30 mg one time per day after consultation with the researcher or physician.
Study NCT05806099 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MBS303
Description: Phase I: The patients confirming to the eligibility criteria will be assigned to one of the 7 dose groups (0.05/0.15/0.45 mg \~ 1.5/6/60 mg, respectively) based on the sequence of inclusion. Each patient will receive MBS303 as per the schedule specified in the respective arms. Based on the safety data of the previous dose groups, if pretreatment with MIL62 is required after disussion by the sponsor and the investigators, the subject should be given an IV infusion of MIL62 1000 mg single dose on the D-7.~Phase Ⅱ: One or two recommended doses will be selected based on the results of Phase I. Each patient will receive one of the two recommended doses MBS303 as step-up doses on D1 (low dose) and D8 (intermediate dose) of C1 and at the target dose on D1 of C2-17 (21-day cycles). Based on the previous safety data, if pretreatment with MIL62 is required after disussion by the sponsor and the investigators, the subjects should be given an IV infusion of MIL62 1000 mg single dose on the D-7
Study NCT05763459 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-CLS-7262
Description: Drug: ABBV-CLS-7262 Drug: Digoxin Drug: Rosuvastatin
Study NCT05051787 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood and milk samples
Description: 2 types of samples will be taken over the same time slots in breastfeeding mothers treated with amoxicillin for at least 2 days:~* 3 breast milk collections of about 20 ml each made using an electric breast pump provided to the participant.~* 3 blood samples of approximately 5 ml each.
Study NCT06433466 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Videos featuring influencers promoting e-cigarettes alongside healthy lifestyle activities
Description: Young adults were randomly shown 10 videos, featuring influencers promoting e-cigarettes alongside healthy lifestyle activities (experimental group), or a healthy lifestyle activity alone (control).
Study NCT06433466 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Videos featuring influencers promoting e-cigarettes alongside healthy lifestyle activities
Description: Young adults were randomly shown 10 videos, featuring influencers promoting e-cigarettes alongside healthy lifestyle activities (experimental group), or a healthy lifestyle activity alone (control).
Study NCT06162819 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amitriptyline
Description: Amitriptyline will be used for prophylaxis of migraine, also used as antidepressant
Study NCT06162819 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flunarizine 5mg
Description: Flunarizine will be used for prophylaxis of migraine,
Study NCT06198517 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moxibustion
Description: The experimental group received moxibustion of Zhongji, Guanyuan, and Qihai for 30 min qd starting on the first day after HSCT was performed until the 14th day after transplantation, while treated conventionally.
Study NCT06198517 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Symptomatic treatment
Description: The control group received conventional symptomatic treatment.
Study NCT05015595 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Memantine Oral Tablet
Description: Thirty-two-week double-blind up-titration treatment period (from T0 to T4): patients will be randomly assigned to one of two arms (Memantine or placebo) in a 1:1 ratio and will receive a daily administration of Memantine/placebo up to 20mg/day. Eight-week double-blind down-titration treatment period (from T4 to T5): At T4, the dose of Memantine/placebo will be reduced at 10mg/day due to safety reasons before the end of treatment (T5).
Study NCT05015595 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Thirty-two-week double-blind up-titration treatment period (from T0 to T4): patients will be randomly assigned to one of two arms (Memantine or placebo) in a 1:1 ratio and will receive a daily administration of Memantine/placebo up to 20mg/day. Eight-week double-blind down-titration treatment period (from T4 to T5): At T4, the dose of Memantine/placebo will be reduced at 10mg/day due to safety reasons before the end of treatment (T5).
Study NCT04874961 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Tensiofytol®
Description: standardized olive extract
Study NCT04874961 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: contains excipients only
Study NCT05253534 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GlaucoT Glaucoma Treatment Device
Description: In this study, flicker light therapy, the effectiveness of which was investigated in the treatment of glaucoma based on some methods used in different diseases, is described for the first time in glaucoma.~Studies investigating the neurodegenerative properties of glaucoma have found similarities in the pathophysiology of Alzheimer's disease and glaucoma.~40 Hz flicker of light Alzheimer 's the positive effects on the knitted cortex have also been shown in studies. 40 Hz flicker light is aimed to reduce glaucoma and retinal ganglion cell loss due to glaucoma, by reducing neurodegeneration by decreasing amyloid and metabolite accumulation by increasing both microglial phagocytic activation effect and retinal blood flow.
Study NCT05553951 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Controlgroup
Description: The control group and intervention group will receive daily text message reminders twice a week to take their medications and to rinse their nose.
Study NCT05094154 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: anti-pseudomonal cephalosporin
Description: Providers will be prompted to order an anti-pseudomonal cephalosporin, such as cefepime with a dose range of 500 mg, 1,000 mg, or 2,000 mg, and frequency every 6, 8, 12, or 24 hours based on provider discretion.
Study NCT05094154 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: anti-pseudomonal penicillin
Description: Providers will be prompted to order anti-pseudomonal penicillin, such as piperacillin-tazobactam with a dose range of 3.375 g or 4.5 g and frequency every 6, 8, or 12 hours based on provider discretion.
Study NCT04429425 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: epidural anesthesia
Description: epidural anesthesia through epidural injection of a local anaesthetic combined with an opioid
Study NCT05553951 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention
Description: Patients in the intervention group will receive systematic and structured nursing guidance regarding their adherence, which includes proper use of nasal irrigation once or twice daily, nasal steroid/drops, use of inhaled medications, follow-up of smoking status. The intervention group will receive guidance videos which have been prepared prior to the study and will be standard for the intervention group. Guidance videos will cover the correct use of nasal irrigation, inhalation steroid, and nasal steroid/drops.
Study NCT06474741 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: in-app notification
Description: Parents will receive bi-weekly prompts in a baby monitor app to change infant's orientation within crib, allow for tummy time several times per day, alternate the side from which infants are fed, alternate the side the infant faces during carrying, and in general note any side preferences of the infant so that positioning can assist in symmetry.
Study NCT05392192 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADX-629
Description: Subjects will be randomized to receive both ADX-629 and placebo in one of two treatment sequences: One group of subjects will receive ADX-629 during the 1st treatment period and matching placebo during the 2nd Treatment while subjects the other sequence/group will receive the matching placebo in the 1st treatment period and ADX-629 in the 2nd treatment period.
Study NCT05392192 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will be randomized to receive both ADX-629 and placebo in one of two treatment sequences: One group of subjects will receive ADX-629 during the 1st treatment period and matching placebo during the 2nd Treatment while subjects the other sequence/group will receive the matching placebo in the 1st treatment period and ADX-629 in the 2nd treatment period.
Study NCT06534671 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: diltiazem
Description: IV diltiazem (0.25 mg/kg) will be given over 2 minutes, with ECG and blood pressure measurements at baseline, 2, 5, 7, 10, 15 and 20 minutes. If at 10 minutes there is no QT shortening, and blood pressure is stable, an additional dose (0.35 mg/kg) will be given with ECG and blood pressure measurements at 17, 20, 22, 25, 30 and 35 minutes.
Study NCT04946448 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FIT diet
Description: Dietary intervention as add-on therapy to biologicals
Study NCT05639920 — intervention group
Intervention type: COMBINATION_PRODUCT
Intervention: Scoreing
Description: Validation of Emergency surgery score in predicting mortality and mortality in Egyptian patients undergoing Emergency laparotomy
Study NCT04562779 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone 380 MG
Description: XR naltrexone to be given once prior to hospital discharge
Study NCT04562779 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine Hydrochloride
Description: IV ketamine infusion to be given once prior to hospital discharge
Study NCT04562779 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced linkage
Description: Includes in-hospital intake at outpatient addiction clinic plus contingency management related to follow-up
Study NCT04562779 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced linkage
Description: Includes in-hospital intake at outpatient addiction clinic plus contingency management related to follow-up
Study NCT05868668 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Focused shockwave
Description: Storz Duolith SD-1 (Storz Medical, Tagerwilen, Switzerland)
Study NCT05868668 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Radial wave
Description: Zimmer enPuls Pro (Zimmer MedizinSysteme GmbH, Neu-Ulm, Germany)
Study NCT05868668 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham treatment
Description: Handheld sham probe
Study NCT05675982 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CAR-T cells monitoring
Description: monitoring of circulating DNA by blood sample
Study NCT05399888 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB080
Description: Administered as specified in the treatment arm.
Study NCT05999851 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Arterial applanation tonometry
Description: Arterial applanation tonometry will be performed at the carotid and femoral level by the PulsePen device (Software WPulsePen version 2.3.1, DiaTecne, Milan, Italy), while the subject is lying in the horizontal position and after 5 minutes of rest.
Study NCT05999851 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: In vivo endothelial glycocalyx measurement
Description: The in vivo microscopy (GlycoCheck system) is performed in the sublingual capillaries during the morning, with the participant sitting on a chair. The sublingual capillaries are visualized using an SDF video microscope (Capiscope handheld, KK Research technology Ltd).
Study NCT05999851 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Serum markers of angiogenesis and endothelial dysfunction
Description: ELISA assays to measure serum circulating markers of angiogenesis and endothelial dysfunction (ANG-1, ANG-2, ET-1, ICAM-1 and VCAM-1).
Study NCT05999851 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Blood chemistry test
Description: Immunochemistry analysis of serum levels of uric acid, total cholesterol, LDL-cholesterol, HDL-cholesterol, Triglycerides, Lipoprotein (a)
Study NCT05399888 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: BIIB080
Description: Administered as specified in the treatment arm.
Study NCT05399888 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB080-matching placebo
Description: Administered as specified in the treatment arm.
Study NCT05399888 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: BIIB080-matching placebo
Description: Administered as specified in the treatment arm.
Study NCT05503420 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Masticatory muscle training exerciser
Description: In addition to the normal stroke rehabilitation training, the participants will be instructed on an active range of motion (AROM) exercise to improve coordination of the masticatory muscles. This part will be performed with a 5-second hold at the end of the range of motion for each motion, with 10 repetitions performed for each motion. In addition, each participant will be provided with a device, a U-shaped apparatus covered by silicon and having 3 small springs inside to provide resistance during chewing to be placed inside the mouth for carrying out a chewing exercise. The participant will be instructed to perform a chewing exercise using the device for around 10 minutes each time, twice a day, and 7 days per week. The exercise includes isotonic and isometric muscle training.
Study NCT06133127 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Frailty assessment
Description: Assessments for all patients : isometric quadriceps strength, malnutrition by RFH-NPT and MNA questionnaires, body composition by circumference and triceps skinfold, frailty by LFI and SPPB, muscle cramps by Cramp questionnaire.
Study NCT05999851 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Serum xanthine oxidase activity
Description: Serum xanthine oxidase (XO) activity will be assessed in blood samples measuring the ability of XO to produce uric acid
Study NCT04008680 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: EQ-5D-5L survey internal consistency
Description: To see how increasing the number of questionnaires affects the internal consistency of the EQ-5D-5L.
Study NCT06173960 — intervention group
Intervention type: DEVICE
Intervention: atherectomy
Description: Jetstream atherectomy in combination with Ranger paclitaxel elution balloon (Drug Coated Balloon (DCB))
Study NCT05274724 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: No teleconsultation during the ambulance journey
Description: Standard will be met according to the current institutional protocol, which does not include teleconsultation. Therefore, the call will be interrupted after guidance from the telemedicine on duty
Study NCT05274724 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Teleconsultation during the ambulance journey
Description: teleconsultation will receive a video call using the free WhatsApp application, made by one of the emergency workers of the Telemedicine Center, using an institutional smartphone. The teleconsultation can be done directly to the patient and/or with the companion who made the call. The telemedicine on-duty officer will then assess the condition during the time the ambulance travels. The ambulance team will contact the Telemedicine Center and inform the on-call person when the ambulance geolocation application informs 2 minutes of estimated time of arrival at the place of care. At this point, the on-call doctor will interrupt the teleconsultation and pass the information on to the ambulance team. The video call will be turned off upon arrival of the ambulance team.
Study NCT05791877 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: pneuRIP
Description: Respiratory sensor to measure pulmonary function
Study NCT05168865 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole 2.5mg
Description: Letrozole 5 mg starting on day 3 of spontaneous menstrual period or after progesterone withdrawal bleeding for five consecutive days.
Study NCT05168865 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole 2.5mg
Description: Letrozole 5 mg starting on day 3 of spontaneous menstrual period or after progesterone withdrawal bleeding for five consecutive days.
Study NCT05348824 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Moringa oleifera leaf
Description: Leaf extract preparation
Study NCT05348824 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium hypochlorite
Description: 2.5% sodium hypochlorite (household bleaching agent)
Study NCT05714670 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Curcumin Oral Capsule
Description: Curcumin 1000 mg Oral Capsule beside the standard of care
Study NCT06611722 — intervention group
Intervention type: OTHER
Intervention: Psychological and Functional Assessment
Description: Assessment of Pain Sources: Patients are grouped based on intra-articular, extra-articular, or combined intra- and extra-articular hip pain.Psychological Assessment: Depression and anxiety are assessed using standardized questionnaires (e.g., BDI for depression, SAS for anxiety).Functional Assessment: Joint function and pain are evaluated using clinical and patient-reported outcome measures.
Study NCT06614387 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Infliximab
Description: Patients meeting the inclusion criteria and not having any of the exclusion criteria will be randomized 1:1 to one of two study arms - intravenous administration of blinded active drug, infliximab or vedolizumab at weeks 0, 2, 6 and 14. Infliximab will be administered at a dose 5mg/kg body weight, and vedolizumab at a dose of 300 mg (body mass > 40 kg) and 10 mg/kg (body mass \< 40kg).
Study NCT06614387 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infliximab
Description: Patients meeting the inclusion criteria and not having any of the exclusion criteria will be randomized 1:1 to one of two study arms - intravenous administration of blinded active drug, infliximab or vedolizumab at weeks 0, 2, 6 and 14. Infliximab will be administered at a dose 5mg/kg body weight, and vedolizumab at a dose of 300 mg (body mass > 40 kg) and 10 mg/kg (body mass \< 40kg).
Study NCT06303778 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stand Down mobile app
Description: The Stand Down mobile app is a smartphone-based stand-alone intervention designed to help persons manage drinking and alcohol-related problems on their own. The app is based on principles of motivational enhancement and cognitive-behavioral therapies and comprises 7 modules organized around 4 goals: (i) Enhance awareness of drinking patterns (assessment and personalized feedback), (ii) Establish and monitor progress towards drinking goal - i.e., moderation or abstinence, (iii) Manage cravings and other problems using in-the-moment tools, and (iv) Connect users with other types of support.
Study NCT06303778 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: Participants assigned to the standard care condition will receive standard MAUD care delivered by their CPSs and will not receive access to SD-App. Three medications, naltrexone, disulfiram, and acamprosate, have been approved by the Federal Drug Administration and topiramate has been recommended by the VA/DoD clinical practice guidelines for SUD. MAUD includes these four medications. All medication decisions will be between the CPS and the Veteran and not influenced by study participation.